A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2)

NCT05836779 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

23

Enrollment

INDUSTRY

Sponsor class

Conditions

Cellulite

Interventions

DRUG: CBL-514 injection

Sponsor

Caliway Biopharmaceuticals Co., Ltd.